Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab : Focus on platelet extracellular vesicles
NUB: B039201214365.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Medicine - 98(2019), 27 vom: 01. Juli, Seite e16164 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Devalet, Bérangère [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
A3ULP0F556 |
|---|
| Anmerkungen: |
Date Completed 15.07.2019 Date Revised 12.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000016164 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298905892 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298905892 | ||
| 003 | DE-627 | ||
| 005 | 20231225095202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000016164 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM298905892 | ||
| 035 | |a (NLM)31277120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Devalet, Bérangère |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab |b Focus on platelet extracellular vesicles |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.07.2019 | ||
| 500 | |a Date Revised 12.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thrombosis are severe complications of paroxysmal nocturnal hemoglobinuria (PNH), effectively reduced by eculizumab. Extracellular vesicles (EVs) may play a central role. The objective of this study was to assess the procoagulant activity of plasma isolated from PNH patients (treated or not by eculizumab) and to quantify their circulating EVs.We iteratively collected the platelet-free-plasma of 17 PNH patients and 16 matched healthy volunteers, quantified their circulating EVs by flow cytometry and evaluated their procoagulant activity by thrombin generation and STA-Procoag-procoagulant phospholipid (PPL) assays.A significant decrease of EVs from platelets (P = .024) and an increase of the STA-Procoag-PPL clotting time (P = .049) was observed after initiation of eculizumab and up to 11 weeks after. This reduction of prothrombotic biomarkers was not observed with the thrombin generation test due to a lack of sensitivity of this assay. Active hemolysis was observed in 90% of patients and elevated D-dimers in 41% of them. However, no significant difference was observed between patients and control subjects regarding the procoagulant activity, the EVs quantity, or the cellular origin. Lactate dehydrogenase (LDH) levels were lower in eculizumab-treated patients compared to nontreated patients (441 vs 2448 IU/L). D-dimers and LDH decreased after administration of eculizumab (mean decrease of 1307 ng/mL and 4159 IU/L, respectively).These observations suggest a decrease of the phospholipid-dependent procoagulant potential of EVs after eculizumab therapy in PNH patients. TRIAL REGISTRATION:: NUB: B039201214365 | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a eculizumab |2 NLM | |
| 650 | 7 | |a A3ULP0F556 |2 NLM | |
| 700 | 1 | |a Wannez, Adeline |e verfasserin |4 aut | |
| 700 | 1 | |a Bailly, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Alpan, Lutfiye |e verfasserin |4 aut | |
| 700 | 1 | |a Gheldof, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Bihin, Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 98(2019), 27 vom: 01. Juli, Seite e16164 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2019 |g number:27 |g day:01 |g month:07 |g pages:e16164 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000016164 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2019 |e 27 |b 01 |c 07 |h e16164 | ||